CompletedPhase 2NCT02021292

Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Studying Chronic thromboembolic pulmonary hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Actelion
Principal Investigator
Kelly Papadakis, MD
Actelion
Intervention
Macitentan(drug)
Enrollment
80 enrolled
Eligibility
18-84 years · All sexes
Timeline
20142016

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02021292 on ClinicalTrials.gov

Other trials for Chronic thromboembolic pulmonary hypertension

Additional recruiting or active studies for the same condition.

See all trials for Chronic thromboembolic pulmonary hypertension

← Back to all trials